Wednesday, october 28 | 10:00 AM ET

Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.


Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.


Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human α–Galactosidase–A protein for the proposed treatment of Fabry disease; OPRX–106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Global Rare Diseases, both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Featured Key Opinion Leader

David Warnock, MD
Emeritus Professor of Medicine at UAB Medicine

David Warnock, M.D. received a BA degree in 1966 from the University of California at Berkeley and received his M.D. degree in 1970 from the University of California, San Francisco. Following a fellowship at the NIH, his positions included Section Chief at the San Francisco VA Medical Center, Director of Nephrology at the University of Alabama at Birmingham (UAB) from 1988 to 2008, and Director of the Office of Human Research at UAB from 2005 to 2008. He served as the Marie K Ingalls Professor of Medicine and the Hilda B. Anderson Endowed Professor in Nephrology at UAB and became an Emeritus Professor of Medicine at UAB in October 2015. Dr. Warnock's focus is on the genetic and environmental factors that contribute to hypertension and chronic kidney disease. The spectrum extends from basic studies of salt and water transport systems to population-based studies of the prevalence of CKD and the association with stroke and heart disease. Another focus is inherited disorders of renal function, with a current emphasis on the renal manifestations of Fabry disease. Additional research interests include acid-base physiology, sodium transport mechanisms, chronic kidney disease, diabetes and kidney disease, and inherited renal diseases. Dr. Warnock has been actively treating Fabry disease since 2001. He started the first US patient on commercial enzyme replacement therapy (Fabrazyme®) in April 2003. He served on the Genzyme/Sanofi North American Fabry Registry Advisory Board as well as their International Advisory Board from 2003 – 2018. Dr. Warnock has been working with the Company as an advisor since 2015. He has published extensively about the diagnosis and management of Fabry disease.


Dror Bashan
President and Chief Executive Officer, Director

Mr. Bashan has served as our President and Chief Executive Officer and as a director of our company since June 2019. He has over 20 years of experience in the pharmaceutical industry with roles ranging from business development, marketing, sales and finance providing him with both cross regional and cross discipline experience and a deep knowledge of the global pharmaceutical and health industries. From 1998 through 2018, he served in a number of senior positions at Teva Pharmaceutical Industries Ltd. Most recently, he served as Teva’s Senior Vice President, Global Business Development, and was involved in strategic alliances, cross-company strategic projects and the acquisition and divestiture of assets. Mr. Bashan holds a BA in Economics and Business Management from the Tel Aviv University and an MBA from the Tel-Aviv University.

Eyal Rubin
Senior Vice President, Chief Financial Officer

Mr. Rubin joined Protalix as its Senior Vice President and Chief Financial Officer in September 2019.  He brings to Protalix more than 20 years of finance and capital markets experience, an extensive background in financial planning and operations, management and strategy and a deep knowledge of the biotechnology and pharmaceutical industries.  Prior to joining Protalix, he served as Executive Vice President and Chief Financial Officer of BrainStorm Cell Therapeutics Inc., a publicly traded biotechnology company, where he was responsible for all corporate finance, accounting and investor relations activities.  Prior to his role at BrainStorm, Mr. Rubin served at Teva Pharmaceutical Industries Ltd. in several roles, most recently as Vice President, Head of Corporate Treasury.  In this role, Mr. Rubin was responsible for Teva’s cash operations and cash management, as well as Teva’s equity and debt capital markets transactions.  Mr. Rubin holds a BA in Financing and IT Systems from the College of Management, Israel, where he graduated Summa Cum Laude with a specialization in Financing and IT Systems, and an MBA from Bar-Ilan University, Israel, where he graduated Summa Cum Laude with a specialization in Finance.

Moderated by:
Jenene Thomas, CEO, JTC Team
© 2020 Virtual Investor. All rights reserved.